Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Mineralys Therapeutics Inc (MLYS)

Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update GlobeNewswire - Wed May 6, 3:05PM CDT

– NDA for lorundrostat in adults with hypertension accepted by FDA; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa., May 06,...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue May 5, 4:34PM CDT

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics Reports First Quarter Results With Lorundrostat Trial Data Still Pending Barchart - Tue May 5, 4:25PM CDT

Barchart Research What to Expect from MLYS Earnings MLYS Generated May 5, 2026 Current Price $29.28 EPS Estimate $$-0.51 Consensus Rating Strong Buy Average Move 6.61% Mineralys Therapeutics Reports First...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference GlobeNewswire - Tue May 5, 7:00AM CDT

RADNOR, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026 GlobeNewswire - Wed Apr 29, 3:05PM CDT

RADNOR, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer GlobeNewswire - Tue Mar 24, 7:00AM CDT

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 16, 3:05PM CDT

RADNOR, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update GlobeNewswire - Thu Mar 12, 3:05PM CDT

–  Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR,...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results GlobeNewswire - Mon Mar 9, 3:30PM CDT

– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure...

MLYS : 29.26 (-1.58%)
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026 GlobeNewswire - Mon Mar 9, 7:00AM CDT

RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities...

MLYS : 29.26 (-1.58%)

Barchart Exclusives

Inflation Has Pushed this Dividend Aristocrat to 52-Week Lows. Why It’s Still Not Quite Time to Buy. Barchart - 7 minutes ago
McDonald's stock is trading near its 52-week lows and has a dividend yield of aroudn 2.7%. However, the stock does not look like a compelling buy yet. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.